P Zabel, P Entzian, K Dalhoff and M Schlaak
Medizinische Klinik Forschungszentrum Borstel, Germany.

The optimal therapy for sarcoidosis remains unclear. Most patients show a short-term response to corticosteroid therapy, but they have to face the risk of significant side effects. Because tumor necrosis factor alpha (TNF) plays a critical role in granuloma formation and sustenance as well as in the progression of sarcoidosis, we investigated pentoxifylline (POF), which exerts TNF-inhibitory activity, as a therapeutic agent in active pulmonary sarcoidosis. Twenty-three previously untreated patients with documented disease progression during the preceding 3 mo were treated with POF (25 mg/kg daily) and followed for 6 mo of therapy. Two patients were lost to follow-up, and three patients discontinued POF therapy because of gastrointestinal side effects; 18 patients were thus evaluated. Eleven patients improved, seven remained stable and, most importantly, none deteriorated. Lung function tests-DL(CO), Pa(O2) and Pa(O2)[exercise]- were significantly improved in the patient group as a whole and increased in a highly significant manner in those who improved. Three patients with corticosteroid-resistant disease progression were additionally treated with a combination of corticosteroids with POF. In all three patients the combination therapy resulted in an immediate complete decrease of disease activity, even after tapering prednisone to 7.5 mg daily or tapering off corticosteroids. These promising results suggest that POF may improve therapeutic regimens in pulmonary sarcoidosis either by sparing or replacing corticosteroids.

This article has been cited by other articles:

				L. C. Zaba, G. P. Smith, M. Sanchez, and S. D. Prystowsky Dendritic Cells in the Pathogenesis of Sarcoidosis Am. J. Respir. Cell Mol. Biol., January 1, 2010; 42(1): 32 - 39. [Abstract] [Full Text] [PDF]

				J. P. Lynch III Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia/Fibrosis, and Sarcoidosis ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 635 - 686. [Full Text] [PDF]

				R. Kim and K. C. Meyer Review: Therapies for interstitial lung disease: past, present and future Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 319 - 338. [Abstract] [PDF]

				A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui Interstitial lung disease guideline Thorax, September 1, 2008; 63(Suppl_5): v1 - v58. [Full Text] [PDF]

				M. A. Judson, R. P. Baughman, U. Costabel, S. Flavin, K. H. Lo, M. S. Kavuru, M. Drent, and the Centocor T48 Sarcoidosis investigators Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial Eur. Respir. J., June 1, 2008; 31(6): 1189 - 1196. [Abstract] [Full Text] [PDF]

				A. Clement and E. Eber Interstitial lung diseases in infants and children Eur. Respir. J., March 1, 2008; 31(3): 658 - 666. [Abstract] [Full Text] [PDF]

				R. P. Baughman, E. E. Lower, D. A. Bradley, L. A. Raymond, and A. Kaufman Etanercept for Refractory Ocular Sarcoidosis: Results of a Double-Blind Randomized Trial Chest, August 1, 2005; 128(2): 1062 - 1047. [Abstract] [Full Text] [PDF]

				J. D. Doty, J. E. Mazur, and M. A. Judson Treatment of Sarcoidosis With Infliximab Chest, March 1, 2005; 127(3): 1064 - 1071. [Abstract] [Full Text] [PDF]

				W. J. Martin II, M. C. Iannuzzi, D. B. Gail, and H. H. Peavy Future Directions in Sarcoidosis Research: Summary of an NHLBI Working Group Am. J. Respir. Crit. Care Med., September 1, 2004; 170(5): 567 - 571. [Abstract] [Full Text] [PDF]

				S. D. Roberts, D. S. Wilkes, R. A. Burgett, and K. S. Knox Refractory Sarcoidosis Responding to Infliximab Chest, November 1, 2003; 124(5): 2028 - 2031. [Abstract] [Full Text] [PDF]

				Z. Tong, H. Dai, B. Chen, Z. Abdoh, J. Guzman, and U. Costabel Inhibition of Cytokine Release From Alveolar Macrophages in Pulmonary Sarcoidosis by Pentoxifylline: Comparison With Dexamethasone Chest, October 1, 2003; 124(4): 1526 - 1532. [Abstract] [Full Text] [PDF]

				J. P. Utz, A. H. Limper, S. Kalra, U. Specks, J. P. Scott, Z. Vuk-Pavlovic, and D. R. Schroeder Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis Chest, July 1, 2003; 124(1): 177 - 185. [Abstract] [Full Text] [PDF]

				V. Majithia, S. Sanders, V. Harisdangkul, and J. G. Wilson Successful treatment of sarcoidosis with leflunomide Rheumatology, May 1, 2003; 42(5): 700 - 702. [Full Text] [PDF]

				J. M. Katz, M. K. Bruno, J. M. S. Winterkorn, and N. Nealon The Pathogenesis and Treatment of Optic Disc Swelling in Neurosarcoidosis: A Unique Therapeutic Response to Infliximab Arch Neurol, March 1, 2003; 60(3): 426 - 430. [Abstract] [Full Text] [PDF]

				P. F. Pollice, R. N. Rosier, R. J. Looney, J. E. Puzas, E. M. Schwarz, and R. J. O'Keefe Oral Pentoxifylline Inhibits Release of Tumor Necrosis Factor-Alpha from Human Peripheral Blood Monocytes : A Potential Treatment for Aseptic Loosening of Total Joint Components J. Bone Joint Surg. Am., July 1, 2001; 83(7): 1057 - 1061. [Abstract] [Full Text] [PDF]

				U. Costabel Sarcoidosis: clinical update Eur. Respir. J., July 1, 2001; 18(32_suppl): 56S - 68s. [Abstract] [Full Text] [PDF]

				G J GIBSON Sarcoidosis: old and new treatments Thorax, May 1, 2001; 56(5): 336 - 339. [Full Text]

				J. P. Callen The Presence of Foreign Bodies Does Not Exclude the Diagnosis of Sarcoidosis Arch Dermatol, April 1, 2001; 137(4): 485 - 486. [Full Text] [PDF]

				E. Yamaguchi, A. Itoh, N. Hizawa, and Y. Kawakami The Gene Polymorphism of Tumor Necrosis Factor-{beta}, But Not That of Tumor Necrosis Factor-{{alpha}}, Is Associated With the Prognosis of Sarcoidosis Chest, March 1, 2001; 119(3): 753 - 761. [Abstract] [Full Text] [PDF]

				G. Hunninghake Statement on Sarcoidosis Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 736 - 755. [Full Text]

				D. M Mitchell and A. Woodcock Introduction Thorax, August 1, 1999; 54(90002): S1 - 1. [PDF]

				M. A. Judson An Approach to the Treatment of Pulmonary Sarcoidosis With Corticosteroids: The Six Phases of Treatment Chest, April 1, 1999; 115(4): 1158 - 1165. [Abstract] [Full Text] [PDF]

				L. J. MARQUES, L. ZHENG, N. POULAKIS, J. GUZMAN, and U. COSTABEL Pentoxifylline Inhibits TNF-alpha Production from Human Alveolar Macrophages Am. J. Respir. Crit. Care Med., February 1, 1999; 159(2): 508 - 511. [Abstract] [Full Text]

				M. W. ZIEGENHAGEN, P. ZABEL, G. ZISSEL, M. SCHLAAK, and J. MULLER-QUERNHEIM Serum Level of Interleukin 8 Is Elevated in Idiopathic Pulmonary Fibrosis and Indicates Disease Activity Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): 762 - 768. [Abstract] [Full Text] [PDF]

				B. T. SOCIETY and S. O. C. COMMITTEE The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations Thorax, April 1, 1990; 54(90001): 1S - 28. [Full Text]